Kiniksa Pharmaceuticals, Ltd.KNSANASDAQ
Loading
Operating Income ScalingExpanding
Percentile Rank100
3Y CAGR+99.2%
Studio
Year-over-Year Change

Profit from core business operations before interest and taxes

3Y CAGR
+99.2%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
7.9x
Strong expansion
Streak
1 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$77.22M+269.3%
2024$-45.62M-81.0%
2023$-25.20M-357.8%
2022$9.77M+106.2%
2021$-156.64M+0.5%
2020$-157.36M+7.4%
2019$-169.96M-57.1%
2018$-108.16M-65.4%
2017$-65.40M-172.5%
2016$-24.00M-